Entrectinib in children and young adults with solid or primary CNS tumors harboring <i>NTRK</i>, <i>ROS1</i>, or <i>ALK</i> aberrations (STARTRK-NG)Ami V. Desai, Elizabeth Fox, Janet Yoon et al.|Neuro-Oncology|2022Cited by 136
Lorlatinib with or without chemotherapy in ALK-driven refractory/relapsed neuroblastoma: phase 1 trial resultsKelly C. Goldsmith, Yaël P. Mossé, Julie R. Park et al.|Nature Medicine|2023Cited by 125
Phase 1/1B trial to assess the activity of entrectinib in children and adolescents with recurrent or refractory solid tumors including central nervous system (CNS) tumors.Giles Robinson, Ami V. Desai, Amar Gajjar et al.|Journal of Clinical Oncology|2019Cited by 61
Progression-Free Survival and Patterns of Response in Patients With Relapsed High-Risk Neuroblastoma Treated With Irinotecan/Temozolomide/Dinutuximab/Granulocyte-Macrophage Colony-Stimulating FactorBenjamin Lerman, Rochelle Bagatell, Yimei Li et al.|Journal of Clinical Oncology|2022Cited by 42
Phase 1 evaluation of EZN-2208, a polyethylene glycol conjugate of SN38, in children adolescents and young adults with relapsed or refractory solid tumorsRobin E. Norris, Rochelle Bagatell, Suzanne Shusterman et al.|Pediatric Blood & Cancer|2014Cited by 34